
Galena’s breast cancer immunotherapy fails in late-stage trials; shares plunge
pharmafile | June 30, 2016 | News story | Research and Development, Sales and Marketing | Galena Biopharma, Stock, breast cancer, drug trial
Shares in Galena Biopharma (Nasdaq: GALE) dropped over 80% after the company said an independent Data Monitoring Committee recommended that the Phase III study of its NeuVax (nelipepimut-S) be stopped due to futility.
Mark Schwartz, chief executive officer, said: “We are extremely disappointed with the outcome of the Present futility analysis.”
The trial was evaluating NeuVax plus GM-CSF versus placebo plus GM-CSF to prevent breast cancer recurrence.
The trial randomised 758 patients with breast cancer, with the primary endpoint being disease-free survival (DFS). Galena said the interim analysis was conducted after 70 qualifying DFS events.
Galena said it is also currently conducting two breast cancer studies of NeuVax in combination with Roche’s Herceptin (trastuzumab), and a separate mid-stage trial. The company said it is also planning Phase II trials with NeuVax for gastric cancer.
Anjali Shukla
Related Content

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Micrima announces upcoming launch of new UK breast cancer assessment
Breast cancer remains one of the leading health threats to women over 35 in the …

Pierre Fabre partners with Know Your Lemons Foundation for breast cancer awareness
The campaign focuses on early detection and education Pierre Fabre Laboratories has announced a partnership …






